SNBL to Acquire Satsuma Pharma

 SNBL to acquire all outstanding shares of Satsuma for upfront cash consideration of $0.91 per share

Satsuma stockholders to also receive non-tradeable CVR of up to $5.77 per share

With the goal of maximizing value for stockholders, Satsuma’s Board has carefully considered strategic options for Satsuma and STS101 and fully supports this transaction with SNBL

https://finance.yahoo.com/news/snbl-acquire-satsuma-pharmaceuticals-234100184.html